TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

Autor:	K. I. Zarubina, E. N. Parovichnikova, O. A. Gavrilina, A. N. Sokolov, V. V. Troitskaya, L. A. Kuzmina, V. E. Mamonov, G. M. Galstyan, V. G. Savchenko
Jazyk:	ruština
Rok vydání:	2017
Předmět:	ph-positive acute lymphoblastic leukemia tyrosine kinase inhibitors selectivity combined toxicity t315i mutation imatinib nilotinib dasatinib axitinib ponatinib blinatumomab Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Онкогематология, Vol 12, Iss 3, Pp 41-49 (2017)
Druh dokumentu:	article
ISSN:	1818-8346 2413-4023
DOI:	10.17650/1818-8346-2017-12-3-41-49
Popis:	A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/ccbc7c4b11d244ae8ba5dbc2e2e7d0c0 Zobrazit plný text záznamu View record in DOAJ